Literature DB >> 11257412

Transcutaneous immunization: T cell responses and boosting of existing immunity.

S A Hammond1, D Walwender, C R Alving, G M Glenn.   

Abstract

Transcutaneous immunization (TCI) is a novel immunization strategy by which antigen and adjuvant are applied topically to intact, hydrated skin to induce potent antibody and cell-mediated immune responses specific for both the antigen and the adjuvant. Using tetanus toxoid as a model antigen, we examined the T cell response to tetanus toxoid after topical immunization with a variety of adjuvants. TCI readily induced systemic antigen specific T cell responses with a mixed Th1/Th2 phenotype but with a Th2 bias. We also investigated whether priming by the intramuscular route, which is known to induce T cell memory, could be followed by a boosting immunization on the skin to induce secondary responses. TCI could augment existing immunity, but interestingly, this strategy induced potent responses only if the antibody titer was low at the time of TCI boosting. These and previous observations suggest that TCI follows known immunological principles that govern other routes of vaccine delivery. Furthermore, booster immunization using tetanus toxoid may provide a useful model for further development of important patch and formulation concepts for TCI, and act as an early candidate for validating product feasibility of TCI in humans.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11257412     DOI: 10.1016/s0264-410x(00)00506-5

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  14 in total

1.  Transcutaneous immunization induces mucosal CTLs and protective immunity by migration of primed skin dendritic cells.

Authors:  Igor M Belyakov; Scott A Hammond; Jeffrey D Ahlers; Gregory M Glenn; Jay A Berzofsky
Journal:  J Clin Invest       Date:  2004-04       Impact factor: 14.808

2.  Skin localization of cow's milk proteins delivered by a new ready-to-use atopy patch test.

Authors:  D Soury; G Barratt; S Ah-Leung; P Legrand; H Chacun; G Ponchel
Journal:  Pharm Res       Date:  2005-08-24       Impact factor: 4.200

3.  Epicutaneous immunization converts subsequent and established antigen-specific T helper type 1 (Th1) to Th2-type responses.

Authors:  Jessica Strid; Robin Callard; Stephan Strobel
Journal:  Immunology       Date:  2006-06-08       Impact factor: 7.397

Review 4.  Topical vaccination: the skin as a unique portal to adaptive immune responses.

Authors:  Chun-Ming Huang
Journal:  Semin Immunopathol       Date:  2007-04       Impact factor: 9.623

5.  Immunological activation following transcutaneous delivery of HR-gp100 protein.

Authors:  Shoshana Frankenburg; Igor Grinberg; Ziva Bazak; Lena Fingerut; Jacob Pitcovski; Raphael Gorodetsky; Tamar Peretz; Ram M Spira; Yehuda Skornik; Ronald S Goldstein
Journal:  Vaccine       Date:  2007-04-25       Impact factor: 3.641

Review 6.  Langerhans cells as targets for immunotherapy against skin cancer.

Authors:  Patrizia Stoitzner; Florian Sparber; Christoph H Tripp
Journal:  Immunol Cell Biol       Date:  2010-03-30       Impact factor: 5.126

7.  Induction and recall of immune memory by mucosal immunization with a non-toxic recombinant enterotoxin-based chimeric protein.

Authors:  Christine M Gockel; Michael W Russell
Journal:  Immunology       Date:  2005-12       Impact factor: 7.397

8.  Preferential amplification of CD8 effector-T cells after transcutaneous application of an inactivated influenza vaccine: a randomized phase I trial.

Authors:  Behazine Combadière; Annika Vogt; Brice Mahé; Dominique Costagliola; Sabrina Hadam; Olivia Bonduelle; Wolfram Sterry; Shlomo Staszewski; Hans Schaefer; Sylvie van der Werf; Christine Katlama; Brigitte Autran; Ulrike Blume-Peytavi
Journal:  PLoS One       Date:  2010-05-26       Impact factor: 3.240

9.  Transcutaneous immunization using colonization factor and heat-labile enterotoxin induces correlates of protective immunity for enterotoxigenic Escherichia coli.

Authors:  Jianmei Yu; Frederick Cassels; Tanya Scharton-Kersten; Scott A Hammond; Antoinette Hartman; Evelina Angov; Blaise Corthésy; Carl Alving; Gregory Glenn
Journal:  Infect Immun       Date:  2002-03       Impact factor: 3.441

10.  Safety and immunogenicity of a prototype enterotoxigenic Escherichia coli vaccine administered transcutaneously.

Authors:  Fernando Güereña-Burgueño; Eric R Hall; David N Taylor; Frederick J Cassels; Daniel A Scott; Marcia K Wolf; Zachary J Roberts; Galina V Nesterova; Carl R Alving; Gregory M Glenn
Journal:  Infect Immun       Date:  2002-04       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.